BX 517: a phosphoinositide-dependent kinase-1 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11161844 |
| CHEMBL ID | 228654 |
| SCHEMBL ID | 5567818 |
| MeSH ID | M0513672 |
| Synonym |
|---|
| bx-517 |
| indolinone based inhibitor, 4i |
| [(3z)-2-oxo-3-[1-(1h-pyrrol-2-yl)ethylidene]-2,3-dihydro-1h-indol-5-yl]urea |
| bdbm17004 |
| bx 517 |
| CHEMBL228654 |
| S6504 |
| 850717-64-5 |
| urea, n-(2,3-dihydro-2-oxo-3-((3z)-1-(1h-pyrrol-2-yl)ethylidene)-1h-indol-5-yl)- |
| syv8vn8w5k , |
| unii-syv8vn8w5k |
| 5-ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one |
| 946843-63-6 |
| urea, n-(2,3-dihydro-2-oxo-3-(1-(1h-pyrrol-2-yl)ethylidene)-1h-indol-5-yl)- |
| urea, (2,3-dihydro-2-oxo-3-(1-(1h-pyrrol-2-yl)ethylidene)-1h-indol-5-yl)- |
| SCHEMBL5567818 |
| bx517 , |
| HY-13842 |
| CS-6066 |
| {2-oxo-3-[1-(1h-pyrrol-2-yl)ethylidene]-2,3-dihydro-1h-indol-5-yl}urea |
| pdk-1 inhibitors |
| AKOS032945106 |
| pdk1 inhibitor2 |
| pdk1 inhibitor ii;bx-517;bx517;bx 517 |
| BCP16225 |
| (z)-1-(3-(1-(1h-pyrrol-2-yl)ethylidene)-2-oxoindolin-5-yl)urea |
| EX-A2243 |
| pdk1 inhibitor 2 |
| [(3z)-2-oxo-3-[1-(1h-pyrrol-2-yl)ethylidene]-1h-indol-5-yl]urea |
| NCGC00486863-01 |
| urea, [2,3-dihydro-2-oxo-3-[1-(1h-pyrrol-2-yl)ethylidene]-1h-indol-5-yl]- |
| Q27289467 |
| F85475 |
| MS-24008 |
| (z)-n-(3-(1-(1h-pyrrol-2-yl)ethylidene)-2-hydroxy-3h-indol-5-yl)carbamimidic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | IC50 (µMol) | 0.0178 | 0.0025 | 1.4513 | 9.0000 | AID1388455; AID1797575; AID1797577; AID1797578; AID291127; AID299513; AID299515; AID729480 |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | IC50 (µMol) | 0.1000 | 0.0002 | 0.7387 | 10.0000 | AID299516 |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | IC50 (µMol) | 0.0050 | 0.0005 | 0.5013 | 7.6000 | AID291126 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID299522 | Selectivity for PDK1 over PKA | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID291131 | Stability in human liver microsomes after 1 hr | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. |
| AID299516 | Inhibition of Akt phosphorylation in PC3 cells | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID291126 | Inhibition of AKT2 | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. |
| AID291130 | Volume of distribution at steady state in rat 5 mg/kg, iv | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. |
| AID299517 | Inhibition of PKA | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID291127 | Inhibition of AKT phosphorylation in PC3 cells | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. |
| AID729480 | Inhibition of PDK1 (unknown origin) | 2013 | Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7 | Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1. |
| AID291128 | Half life in rat at 5 mg/kg, iv | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. |
| AID291132 | Solubility in PBS | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. |
| AID299521 | Oral bioavailability in rat at 10 mg/kg | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID1388455 | Inhibition of PDK1 (unknown origin) after 1 hr in presence of Ser/Thr-07 by fluorometric assay | 2017 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24 | Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors. |
| AID299513 | Inhibition of PDK1 mediated cAKT2 phosphorylation by AKT2 activation assay | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID291129 | Clearance in rat at 5 mg/kg, iv | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. |
| AID299518 | Solubility in phosphate buffered saline | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID299520 | Clearance in rat at 2 mg/kg, iv | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID299515 | Inhibition of PDK1 | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID299519 | Half life in rat at 2 mg/kg, iv | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1797578 | PDK1 Activity Assay (33P-filter paper) from Article 10.1016/j.bmcl.2007.04.071: \\Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.\\ | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID1797577 | PDK1-mediated AKT2 Activation Assay (cAKT2 33P-SPA) from Article 10.1016/j.bmcl.2007.04.071: \\Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.\\ | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. |
| AID1797575 | PDK1-mediated AKT2 Activation Assay (cAKT2 33P-SPA) from Article 10.1016/j.bmcl.2007.05.060: \\Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.\\ | 2007 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14 | Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||